DarioHealth Corp. announced on November 4, 2024, a new collaboration with a top six U.S. pharmaceutical company. This partnership will utilize Dario Connect, formerly Twill Care, to enhance user engagement among patients prescribed a new drug for psoriasis. This collaboration represents a strategic shift in Dario's pharma channel, moving from milestone-based payments to a recurring service subscription fee structure.
The initiative is designed to help onboard patients and collect critical insights on patient outcomes and drug effectiveness. Dario Connect's community-building capabilities are expected to play a key role in boosting patient engagement. The financial arrangement includes an initial fixed configuration fee, followed by ongoing platform and services subscription fees.
Steven Nelson, Chief Commercial Officer of DarioHealth, highlighted that this advanced approach aims to redefine how pharmaceutical companies engage with patients. He anticipates more recurring revenue-based collaborations in the pharma channel going forward, underscoring the momentum in this segment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.